These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 23110940)

  • 61. Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis.
    Wang C; Lu X; Lyu Z; Bi N; Wang L
    Lung Cancer; 2018 Aug; 122():94-99. PubMed ID: 30032853
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
    Saruwatari K; Ikeda T; Saeki S; Shingu N; Imamura K; Komatu T; Ushijima S; Maruyama H; Kashiwabara K; Tomita Y; Ichiyasu H; Fujii K; Sakagami T
    Anticancer Res; 2019 Feb; 39(2):923-931. PubMed ID: 30711977
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors.
    Lee JH; Chen HY; Hsu FM; Chen JS; Liao WY; Shih JY; Yu CJ; Chen KY; Tsai TH; Yang JC
    Oncologist; 2019 Dec; 24(12):e1417-e1425. PubMed ID: 31127020
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Isolated Brain Metastases as the First Relapse After the Curative Surgical Resection in Non-Small-Cell Lung Cancer Patients With an EGFR Mutation.
    Sadoyama S; Sekine A; Satoh H; Iwasawa T; Kato T; Ikeda S; Sata M; Baba T; Tabata E; Minami Y; Nemoto K; Hayashihara K; Saito T; Okudela K; Ohashi K; Tajiri M; Ogura T
    Clin Lung Cancer; 2018 Jan; 19(1):e29-e36. PubMed ID: 28669848
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
    Zhou L; He J; Xiong W; Liu Y; Xiang J; Yu Q; Liang M; Zhou X; Ding Z; Huang M; Ren L; Zhu J; Li L; Hou M; Ding L; Tan F; Lu Y
    Lung Cancer; 2016 Jun; 96():93-100. PubMed ID: 27133757
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer.
    Li H; Zhang X; Cao J; Su P; Lian J; Song X; Yang W; Han S; Xi Y; Wang Y
    Tumour Biol; 2015 Dec; 36(12):9251-8. PubMed ID: 26091796
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
    Ke SB; Qiu H; Chen JM; Shi W; Chen YS
    Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.
    Doherty MK; Korpanty GJ; Tomasini P; Alizadeh M; Jao K; Labbé C; Mascaux CM; Martin P; Kamel-Reid S; Tsao MS; Pintilie M; Liu G; Bradbury PA; Feld R; Leighl NB; Chung C; Shepherd FA
    Radiother Oncol; 2017 May; 123(2):195-202. PubMed ID: 28363487
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey.
    Unal OU; Oztop I; Calibasi G; Baskin Y; Koca D; Demir N; Akman T; Ellidokuz H; Yilmaz AU
    Asian Pac J Cancer Prev; 2013; 14(6):3705-9. PubMed ID: 23886169
    [TBL] [Abstract][Full Text] [Related]  

  • 71. EGFR mutation status on brain metastases from non-small cell lung cancer.
    Hsu F; De Caluwe A; Anderson D; Nichol A; Toriumi T; Ho C
    Lung Cancer; 2016 Jun; 96():101-7. PubMed ID: 27133758
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Brain surgery in combination with tyrosine kinase inhibitor and whole brain radiotherapy for epidermal growth factor receptor-mutant non-small-cell lung cancer with brain metastases.
    Lee HH; Chen CH; Chuang HY; Huang YW; Huang MY
    Sci Rep; 2019 Nov; 9(1):16834. PubMed ID: 31728013
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
    Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dynamic changes in the systemic immune-inflammation index predict the prognosis of EGFR-mutant lung adenocarcinoma patients receiving brain metastasis radiotherapy.
    Wang Q; Tan X; Deng G; Fu S; Li J; Li Z
    BMC Pulm Med; 2022 Mar; 22(1):75. PubMed ID: 35241046
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
    D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
    J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score.
    Lee DW; Shin DY; Kim JW; Keam B; Kim TM; Kim HJ; Kim DW; Wu HG; Paek SH; Kim YW; Heo DS; Kim DG; Lee SH
    Lung Cancer; 2014 Dec; 86(3):363-8. PubMed ID: 25453849
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study.
    Kashiwabara K; Fujii S; Tsumura S; Sakamoto K
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):287-293. PubMed ID: 32761377
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study.
    Zhen J; Wen L; Lai M; Zhou Z; Shan C; Li S; Lin T; Wu J; Wang W; Xu S; Liu D; Lu M; Zhu D; Chen L; Cai L; Zhou C
    Radiat Oncol; 2020 Jul; 15(1):185. PubMed ID: 32736566
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy.
    Shah PP; Franke JL; Medikonda R; Jackson CM; Srivastava S; Choi J; Forde PM; Brahmer JR; Ettinger DS; Feliciano JL; Levy BP; Marrone KA; Naidoo J; Redmond KJ; Kleinberg LR; Lim M
    J Neurosurg; 2022 Jan; 136(1):56-66. PubMed ID: 34087798
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
    Lee VH; Tin VP; Choy TS; Lam KO; Choi CW; Chung LP; Tsang JW; Ho PP; Leung DK; Ma ES; Liu J; Shek TW; Kwong DL; Leung TW; Wong MP
    J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.